إعلان
إعلان
URGN
UroGen Pharma Ltd. Ordinary Shares
21.25
USDبرعاية
-2.24
-9.54%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
قبل الإفتتاح
21.33
+0.08
+0.38%
تقارير أرباح URGN
النسبة الإيجابية المفاجئة
URGN تفوق 16 من 34 آخر التقديرات.
47%
التقرير التالي
بيانات التقرير القادم
٠٩ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$42.28M
/-$0.49
التغير الضمني من Q3 25 (Revenue/ EPS)
+53.84%
/-28.99%
التغير الضمني من Q4 24 (Revenue/ EPS)
+72.11%
/-38.75%
UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, URGN reported earnings of -0.69 USD per share (EPS) for Q3 25, beating the estimate of -0.70 USD, resulting in a 2.32% surprise. Revenue reached 27.48 مليون, compared to an expected 33.76 مليون, with a -18.58% difference. The market reacted with a +21.91% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 المحللين forecast an EPS of -0.49 USD, with revenue projected to reach 42.28 مليون USD, implying an نقصان of -28.99% EPS, and زيادة of 53.84% in Revenue from the last quarter.
الأسئلة الشائعة
What were UroGen Pharma Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.69, beating estimates by 2.32%, and revenue of $27.48M, -18.58% below expectations.
How did the market react to UroGen Pharma Ltd. Ordinary Shares's Q3 2025 earnings?
The stock price moved up 21.91%, changed from $19.31 before the earnings release to $23.54 the day after.
When is UroGen Pharma Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for ٠٩ مارس ٢٠٢٦.
What are the forecasts for UroGen Pharma Ltd. Ordinary Shares's next earnings report?
Based on 10
المحللين, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of -$0.49 and revenue of $42.28M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان